WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

This group comprises all hormonal preparations for systemic use, except:

- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.


H03 THYROID THERAPY

H03A THYROID PREPARATIONS

This group comprises thyroid extracts and synthetic analogues used in the treatment of hypothyrosis.

The DDDs are based on the treatment of hypothyrosis.

H03B ANTITHYROID PREPARATIONS

This group comprises preparations used in the treatment of hyperthyrosis.

The DDDs are based on the treatment of hyperthyrosis.

H03C IODINE THERAPY

This group comprises iodine preparations for systemic use.

Last updated: 2017-12-20